Document is current
Any future updates will be listed below
-
Authors
Zhang, Chi
Lu, Yu-Jing https://orcid.org/0000-0003-2494-843X
Wang, Mei
Chen, Bingjie
Xiong, Feifei
Mitsopoulos, Costas
Rossanese, Olivia
Li, Xiuling
Clarke, Paul A. https://orcid.org/0000-0001-9342-1290
- License Information
-
More Information
Article History
Received: 16 November 2023
Revised: 30 August 2024
Accepted: 13 September 2024
First Online: 25 September 2024
Competing interests
: CZ, KM, OR, and PAC are current or past employees of The Institute of Cancer Research, which has a commercial interest in the discovery and development of A3B inhibitors and operates a reward to inventors’ scheme. Separately, CZ, MW, FX, and XL are employees of Shanghai Institute of Biological Products, an entity presently engaged in the commercial development of therapeutic biologics. No conflicts of interest have been reported by the remaining authors.
: The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations.
